Naghmeh Abbasi Kasbi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Naghmeh Abbasi Kasbi has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Agastya Reddy Malladi
Department of Neurology, University of Texas Southwestern Medical Center, Dallas, TX, USA
1 shared publication - Delaram Eskandari
M.D., Endocrinologist Assistant Professor of Internal Medicine Assistant Professor of Internal Medicine, Iran University of Medical Sciences at Rasool Akram General Hospital, Tehran, Iran.
1 shared publication - Fahimeh Soheilipour
Minimally Invasive Surgery Research Center, Iran University of Medical Sciences, Tehran, Iran
1 shared publication - Hassan Asadigandomani
Department of Ophthalmology, University of California San Francisco, San Francisco, CA 94143, USA
1 shared publication - Hora Heidari
Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran
1 shared publication - Jeffrey A. Cohen
Mellen Center, Neurologic Institute, Cleveland Clinic, Cleveland, USA
1 shared publication
Latest Publications
- Open Access
- 21 July 2026
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 32 (11) , 1129-1138
Induced pluripotent stem cell treatment for microglia replacement in progressive MS
Background: Induced pluripotent stem cells (iPSCs) offer a novel approach to target microglia, key drivers of multiple sclerosis (MS) pathology. A promising therapeutic strategy involves depleting resident microglia using colony-stimulating factor 1 receptor (CSF-1R) inhibitors, followed by differentiating iPSCs into microglia in vitro and transplanting them into the central nervous system (CNS). However, no studies have yet specifically examined iPSC-derived microglial replacement in MS. Objectives: This review evaluates the feasibility of replacing pathogenic microglia in MS with iPSC-derived microglia. Methods: A systematic literature search identified studies on microglial depletion, iPSC differentiation into microglia, and transplantation, as well as reports involving other MS-relevant neural cell types. Results: Direct studies on iPSC-derived microglia transplantation in MS are currently lacking; however, several preclinical investigations using iPSC-derived neural stem cells and oligodendrocyte precursor cells in animal models demonstrate robust engraftment, targeted migration to demyelinated lesions, reduced inflammation, enhanced remyelination, and significant functional recovery in vivo. These findings, besides microglia-specific transplantation, depletion, and repopulation studies in other disease contexts, support the biological plausibility of iPSC-based CNS cell replacement and inform future microglial transplantation research. Conclusion: Replacing pathogenic microglia with iPSC-derived counterparts represents an emerging therapeutic avenue for progressive MS. Rigorous preclinical studies are needed to confirm safety, optimize transplantation, and evaluate long-term efficacy.
- 21 July 2026
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 32 (11) , 1129-1138
Open AccessInduced pluripotent stem cell treatment for microglia replacement in progressive MS
Background: Induced pluripotent stem cells (iPSCs) offer a novel approach to target microglia, key drivers of multiple sclerosis (MS) pathology. A promising therapeutic strategy involves depleting resident microglia using colony-stimulating factor 1 receptor (CSF-1R) inhibitors, followed by differentiating iPSCs into microglia in vitro and transplanting them into the central nervous system (CNS). However, no studies have yet specifically examined iPSC-derived microglial replacement in MS. Objectives: This review evaluates the feasibility of replacing pathogenic microglia in MS with iPSC-derived microglia. Methods: A systematic literature search identified studies on microglial depletion, iPSC differentiation into microglia, and transplantation, as well as reports involving other MS-relevant neural cell types. Results: Direct studies on iPSC-derived microglia transplantation in MS are currently lacking; however, several preclinical investigations using iPSC-derived neural stem cells and oligodendrocyte precursor cells in animal models demonstrate robust engraftment, targeted migration to demyelinated lesions, reduced inflammation, enhanced remyelination, and significant functional recovery in vivo. These findings, besides microglia-specific transplantation, depletion, and repopulation studies in other disease contexts, support the biological plausibility of iPSC-based CNS cell replacement and inform future microglial transplantation research. Conclusion: Replacing pathogenic microglia with iPSC-derived counterparts represents an emerging therapeutic avenue for progressive MS. Rigorous preclinical studies are needed to confirm safety, optimize transplantation, and evaluate long-term efficacy.
- 4 September 2024
- Published by Springer Nature in Neurological Sciences
- Vol. 46 (1) , 351-364
The coincidence of multiple sclerosis and primary vasculitis; from the bench of pathology to the bedside of treatment: a systematic review of case reports
Multiple sclerosis (MS) is a chronic, disabling neurodegenerative disease, leads to reduced quality of life. The increasing prevalence of MS around the wor
- 4 September 2024
- Published by Springer Nature in Neurological Sciences
- Vol. 46 (1) , 351-364
The coincidence of multiple sclerosis and primary vasculitis; from the bench of pathology to the bedside of treatment: a systematic review of case reports
Multiple sclerosis (MS) is a chronic, disabling neurodegenerative disease, leads to reduced quality of life. The increasing prevalence of MS around the wor
- Open Access
- 6 August 2023
- Published by Brieflands in International Journal of Endocrinology and Metabolism
- Vol. 21 (3) , e135004
Complications and Treatment of Early-Onset Type 2 Diabetes
Context: Global reports have revealed a dramatic rise in the number of patients diagnosed with type 2 diabetes (T2DM) over the past three decades in all age groups, even in children and adolescents. The physiologic phenomenon of insulin resistance during puberty, as well as genetic and epigenetic factors, are implicated in this phenomenon. It seems that patients with early-onset T2DM experience a more aggressive clinical course; however, limited treatments available for these patients pose a challenge. This narrative review intends to scrutinize the micro- and macrovascular complications and treatments of patients with early-onset T2DM. Methods: The literature search was conducted in the PubMed database to identify all relevant original English articles published from the beginning of 2018 until January 2023. Results: Vascular complications, such as albuminuria, hypertension, cardiovascular diseases, and retinopathy, were seen to be more common in early-onset T2DM compared to type 1 diabetes. The odds ratio of vascular complications was higher in early-onset compared to late-onset T2DM. In children and adolescents with T2DM, the only approved medications included metformin, insulin, and glucagon-like peptide-1 agonists. Treatment of early-onset T2DM with metformin monotherapy cannot yield durable glycemic control, and most patients need early combination therapy. Conclusions: During the past years, the frequency of early-onset T2DM has been growing at an alarming rate. Vascular complications in these patients seem more aggressive and more challenging to control. Hence, further clinical trials should be conducted to develop novel therapeutic approaches and evaluate their long-term benefits in terms of glycemic control and preventing future complications.
- 6 August 2023
- Published by Brieflands in International Journal of Endocrinology and Metabolism
- Vol. 21 (3) , e135004
Open AccessComplications and Treatment of Early-Onset Type 2 Diabetes
Context: Global reports have revealed a dramatic rise in the number of patients diagnosed with type 2 diabetes (T2DM) over the past three decades in all age groups, even in children and adolescents. The physiologic phenomenon of insulin resistance during puberty, as well as genetic and epigenetic factors, are implicated in this phenomenon. It seems that patients with early-onset T2DM experience a more aggressive clinical course; however, limited treatments available for these patients pose a challenge. This narrative review intends to scrutinize the micro- and macrovascular complications and treatments of patients with early-onset T2DM. Methods: The literature search was conducted in the PubMed database to identify all relevant original English articles published from the beginning of 2018 until January 2023. Results: Vascular complications, such as albuminuria, hypertension, cardiovascular diseases, and retinopathy, were seen to be more common in early-onset T2DM compared to type 1 diabetes. The odds ratio of vascular complications was higher in early-onset compared to late-onset T2DM. In children and adolescents with T2DM, the only approved medications included metformin, insulin, and glucagon-like peptide-1 agonists. Treatment of early-onset T2DM with metformin monotherapy cannot yield durable glycemic control, and most patients need early combination therapy. Conclusions: During the past years, the frequency of early-onset T2DM has been growing at an alarming rate. Vascular complications in these patients seem more aggressive and more challenging to control. Hence, further clinical trials should be conducted to develop novel therapeutic approaches and evaluate their long-term benefits in terms of glycemic control and preventing future complications.